Johnson & Johnson

Johnson & Johnson

Organization

Heard in 185 episodes across 50 shows since Sep 2025

Johnson & Johnson is an American multinational healthcare company focused on pharmaceutical medicines and medical technologies, including medical devices. The podcast references primarily concern the publicly traded parent company, its pharmaceutical and medical-device businesses, earnings and stock performance, and its former consumer-health portfolio, which was separated into Kenvue in 2023 rather than remaining part of J&J.

Discussed inMarkets77%AI & Tech14%Business5%Politics2%

Episodes

185
across 50 shows

This week

0
episodes on 0 shows

Expert statements

68
63 positive · 2 negative

Share of the conversation

Mentions of Johnson & Johnson per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.05‰0.1‰0.15‰0.2‰Aug 25Sep 16Oct 9Oct 31Nov 22
Show the data
DayShare (7-day)Mentions
Oct 130.17‰10
Oct 140.17‰2
Oct 150.18‰2
Oct 160.19‰4
Oct 190.19‰4
Oct 200.12‰2
Oct 210.15‰6
Oct 220.15‰2
Oct 260.11‰3
Oct 270.12‰3
Oct 280.07‰1
Oct 290.08‰2
Oct 300.09‰2
Oct 310.10‰1
Nov 20.08‰1
Nov 30.08‰2
Nov 40.07‰1
Nov 50.08‰3
Nov 60.08‰2
Nov 90.07‰1
Nov 100.06‰1
Nov 120.07‰4
Nov 130.06‰1
Nov 140.08‰3
Nov 160.09‰3
Nov 170.11‰3
Nov 180.13‰2
Nov 190.10‰1
Nov 200.11‰2
Nov 220.10‰1

The full trend: rank, tone and why it is trending →

Email alert

Email me when Johnson & Johnson comes up on a podcast

One email a week at most, with the new episodes that mention Johnson & Johnson. Free, no account needed, unsubscribe in one click.

What experts have said about Johnson & Johnson

68 statements · 63 positive · 2 negative · 1 mixed · 2 neutral

  1. Lauren MartzNeutralNov 17, 2026· BioCentury This Week

    The Allen transaction includes more than $1.1 billion in regulatory and commercial milestones.

    “There's another 1.1 or a little more. in regulatory and commercial milestones.”

    Listen at 2:18

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  2. John CerteauNeutralNov 16, 2026· Brew Markets

    Johnson & Johnson is buying All In Biosciences for over $2 billion.

    “the drugmaker is buying iDisease Biotech Company All In Biosciences for over $2 billion.”

    Listen at 17:04

    Open the episode · NVIDIA's China Loophole & The Aviation Blame Game
  3. Contessa BrewerPositiveNov 14, 2026· CNBC's "Fast Money"

    Johnson & Johnson will likely continue growth and dividend payments.

    “I think you're gonna likely continue to see some growth, continue to see that dividend.”

    Listen at 37:29

    Open the episode · Fast Money: FAA Ground Stop, Anthropic IPO and AI Market Rotation 11/13/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

185 episodes featuring Johnson & Johnson, newest first